127 related articles for article (PubMed ID: 9374386)
1. Phase IB study of doxorubicin in combination with the multidrug resistance reversing agent S9788 in advanced colorectal and renal cell cancer.
Punt CJ; Voest EE; Tueni E; Van Oosterom AT; Backx A; De Mulder PH; Hecquet B; Lucas C; Gerard B; Bleiberg H
Br J Cancer; 1997; 76(10):1376-81. PubMed ID: 9374386
[TBL] [Abstract][Full Text] [Related]
2. Phase I clinical and pharmacokinetic study of S9788, a new multidrug-resistance reversal agent given alone and in combination with doxorubicin to patients with advanced solid tumors.
Tranchand B; Catimel G; Lucas C; Sarkany M; Bastian G; Evene E; Guastalla JP; Négrier S; Rebattu P; Dumortier A; Foy M; Grossin F; Mazier B; Froudarakis M; Barbet N; Clavel M; Ardiet C
Cancer Chemother Pharmacol; 1998; 41(4):281-91. PubMed ID: 9488597
[TBL] [Abstract][Full Text] [Related]
3. Ventricular arrhythmia and torsade de pointe: dose limiting toxicities of the MDR-modulator S9788 in a phase I trial.
Stupp R; Bauer J; Pagani O; Gerard B; Cerny T; Sessa C; Bastian G; Sarkany M; Schläpfer J; Giroux B; Leyvraz S
Ann Oncol; 1998 Nov; 9(11):1233-42. PubMed ID: 9862055
[TBL] [Abstract][Full Text] [Related]
4. Multidrug resistance circumvention by a new triazinoaminopiperidine derivative S9788 in vitro: definition of the optimal schedule and comparison with verapamil.
Julia AM; Roché H; Berlion M; Lucas C; Milano G; Robert J; Bizzari JP; Canal P
Br J Cancer; 1994 May; 69(5):868-74. PubMed ID: 8180016
[TBL] [Abstract][Full Text] [Related]
5. Phase I and pharmacokinetic study of paclitaxel in combination with biricodar, a novel agent that reverses multidrug resistance conferred by overexpression of both MDR1 and MRP.
Rowinsky EK; Smith L; Wang YM; Chaturvedi P; Villalona M; Campbell E; Aylesworth C; Eckhardt SG; Hammond L; Kraynak M; Drengler R; Stephenson J; Harding MW; Von Hoff DD
J Clin Oncol; 1998 Sep; 16(9):2964-76. PubMed ID: 9738565
[TBL] [Abstract][Full Text] [Related]
6. Phase I/II trial of the multidrug-resistance modulator valspodar combined with cisplatin and doxorubicin in refractory ovarian cancer.
Baekelandt M; Lehne G; Tropé CG; Szántó I; Pfeiffer P; Gustavssson B; Kristensen GB
J Clin Oncol; 2001 Jun; 19(12):2983-93. PubMed ID: 11408493
[TBL] [Abstract][Full Text] [Related]
7. Safety and efficacy of the multidrug-resistance inhibitor biricodar (VX-710) with concurrent doxorubicin in patients with anthracycline-resistant advanced soft tissue sarcoma.
Bramwell VH; Morris D; Ernst DS; Hings I; Blackstein M; Venner PM; Ette EI; Harding MW; Waxman A; Demetri GD
Clin Cancer Res; 2002 Feb; 8(2):383-93. PubMed ID: 11839653
[TBL] [Abstract][Full Text] [Related]
8. [Pharmacological properties of S9788, a new modulator of multidrug resistance].
Bull Cancer; 1994 Feb; 81(2):93-103. PubMed ID: 7894124
[TBL] [Abstract][Full Text] [Related]
9. Effect of duration of exposure to S9788, cyclosporin A or verapamil on sensitivity of multidrug resistant cells to vincristine or doxorubicin.
Pérez V; Pierré A; Léonce S; Anstett M; Atassi G
Anticancer Res; 1993; 13(4):985-90. PubMed ID: 8352569
[TBL] [Abstract][Full Text] [Related]
10. [In vitro characterization of S9788, a new modulator of multidrug resistance].
Pérez V; Pierré A; Léonce S; Anstett M; Prost JF; Atassi G
Bull Cancer; 1993 Apr; 80(4):310-25. PubMed ID: 8173185
[TBL] [Abstract][Full Text] [Related]
11. A phase I and pharmacologic study of the MDR converter GF120918 in combination with doxorubicin in patients with advanced solid tumors.
Planting AS; Sonneveld P; van der Gaast A; Sparreboom A; van der Burg ME; Luyten GP; de Leeuw K; de Boer-Dennert M; Wissel PS; Jewell RC; Paul EM; Purvis NB; Verweij J
Cancer Chemother Pharmacol; 2005 Jan; 55(1):91-9. PubMed ID: 15565444
[TBL] [Abstract][Full Text] [Related]
12. Effect of S9788 on the efficiency of doxorubicin in vivo and in vitro in medullary thyroid carcinoma xenograft.
Massart C; Gibassier J; Raoul M; Denais A; Maugendre S; Darcel F; Lucas C
Anticancer Drugs; 1996 May; 7(3):321-30. PubMed ID: 8792007
[TBL] [Abstract][Full Text] [Related]
13. Reversal of multidrug resistance by a new lipophilic cationic molecule, S9788. Comparison with 11 other MDR-modulating agents in a model of doxorubicin-resistant rat glioblastoma cells.
Huet S; Chapey C; Robert J
Eur J Cancer; 1993; 29A(10):1377-83. PubMed ID: 8398262
[TBL] [Abstract][Full Text] [Related]
14. [Effect of quinine on the multiple drug resistance and intracellular distribution of pirarubicin in LR73 tumor cells: a comparative study with verapamil and S9788 by confocal laser microspectrofluorometry].
Belhoussine R; Morjani H; Manfait M
Bull Cancer; 1997 Apr; 84(4):343-9. PubMed ID: 9238156
[TBL] [Abstract][Full Text] [Related]
15. Effect of S9788, cyclosporin A and verapamil on intracellular distribution of THP-doxorubicin in multidrug-resistant K562 tumor cells, as studied by laser confocal microspectrofluorometry.
Sebille S; Morjani H; Poullain MG; Manfait M
Anticancer Res; 1994; 14(6A):2389-93. PubMed ID: 7825978
[TBL] [Abstract][Full Text] [Related]
16. Phase I study of cinchonine, a multidrug resistance reversing agent, combined with the CHVP regimen in relapsed and refractory lymphoproliferative syndromes.
Solary E; Mannone L; Moreau D; Caillot D; Casasnovas RO; Guy H; Grandjean M; Wolf JE; André F; Fenaux P; Canal P; Chauffert B; Wotawa A; Bayssas M; Genne P
Leukemia; 2000 Dec; 14(12):2085-94. PubMed ID: 11187897
[TBL] [Abstract][Full Text] [Related]
17. Phase I and pharmacokinetic study of the novel MDR1 and MRP1 inhibitor biricodar administered alone and in combination with doxorubicin.
Peck RA; Hewett J; Harding MW; Wang YM; Chaturvedi PR; Bhatnagar A; Ziessman H; Atkins F; Hawkins MJ
J Clin Oncol; 2001 Jun; 19(12):3130-41. PubMed ID: 11408511
[TBL] [Abstract][Full Text] [Related]
18. Evaluation of toremifene for reversal of multidrug resistance in renal cell cancer patients treated with vinblastine.
Braybrooke JP; Vallis KA; Houlbrook S; Rockett H; Ellmén J; Anttila M; Ganesan TS; Harris AL; Talbot DC
Cancer Chemother Pharmacol; 2000; 46(1):27-34. PubMed ID: 10912574
[TBL] [Abstract][Full Text] [Related]
19. Comparative evaluation of S9788, verapamil, and cyclosporine A in K562 human leukemia cell lines and in P-glycoprotein-expressing samples from patients with hematologic malignancies.
Merlin JL; Guerci A; Marchal S; Missoum N; Ramacci C; Humbert JC; Tsuruo T; Guerci O
Blood; 1994 Jul; 84(1):262-9. PubMed ID: 7912556
[TBL] [Abstract][Full Text] [Related]
20. Reversal of multidrug resistance by SDZ PSC 833, combined with VAD (vincristine, doxorubicin, dexamethasone) in refractory multiple myeloma. A phase I study.
Sonneveld P; Marie JP; Huisman C; Vekhoff A; Schoester M; Faussat AM; van Kapel J; Groenewegen A; Charnick S; Zittoun R; Löwenberg B
Leukemia; 1996 Nov; 10(11):1741-50. PubMed ID: 8892677
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]